x
Filter:
Filters applied
- Concise Reviews for Primary-Care Physicians
- FDARemove FDA filter
Publication Date
Please choose a date range between 1997 and 2020.
Author
- Casey, Petra M2
- Clarke, Bart L2
- Ebbert, Jon O2
- Files, Julia A2
- Lapid, Maria I2
- Marnach, Mary L2
- Agunwamba, Amenah A1
- Alexander, Jeffrey A1
- Bardia, Aditya1
- Bauer, Brent A1
- Blair, Janis E1
- Boatwright, Elizabeth A1
- Bohm, Parker E1
- Bostwick, J Michael1
- Bostwick, John Michael1
- Burke, Michael V1
- Burnett, John C Jr1
- Chen, Horng H1
- Clark, Matthew M1
- Cook, David A1
- David, Paru S1
- Drake, Matthew T1
- Faubion, Stephanie S1
- Fitzpatrick, Lorraine A1
- Frey, Keith A1
Keyword
- Food and Drug Administration20
- BMD3
- HIV3
- human immunodeficiency virus3
- nonsteroidal anti-inflammatory drug3
- NSAID3
- US Food and Drug Administration3
- acquired immunodeficiency syndrome2
- AIDS2
- BMI2
- CDC2
- Centers for Disease Control and Prevention2
- 104-mg medroxyprogesterone acetate1
- ACIP1
- ACOG1
- ACR1
- Advisory Committee on Immunization Practices1
- AGS1
- AI1
- AKI1
- Alcohol Use Disorders Identification Test1
- American College of Obstetrics and Gynecology1
- ANP1
- AUDIT1
Concise Reviews for Primary-Care Physicians
24 Results
- Concise review
Evaluation and Treatment of Overactive Bladder in Women
Mayo Clinic ProceedingsVol. 95Issue 2p370–377Published in issue: February, 2020- Rubin Raju
- Brian J. Linder
Cited in Scopus: 26Overactive bladder (OAB) is a symptom complex that includes urinary urgency, frequency, urgency incontinence, and nocturia. It is highly prevalent, affecting up to 12% of the adult population, and can significantly impact quality of life. The diagnosis of OAB is made by history, physical examination, and a urinalysis to rule out underlying infection or other concerning potential etiologies. The need for additional testing is based on the initial evaluation findings, and is recommended in cases of underlying urinary tract infection, microscopic hematuria, obstructive voiding symptoms, and symptoms refractory to previous treatments. - Concise review for clinicians
Institutional Review Boards: What Clinician Researchers Need to Know
Mayo Clinic ProceedingsVol. 94Issue 3p515–525Published in issue: March, 2019- Maria I. Lapid
- Bart L. Clarke
- R. Scott Wright
Cited in Scopus: 13The institutional review board (IRB) is a group federally mandated to review and monitor research involving humans to ensure protection of their rights and welfare as research participants. Clinicians engaged in research require IRB approval for all research involving human participants, whether living individuals, data, or specimens. The process for obtaining IRB approval may seem like a daunting task. However, it is critical for clinical researchers to conduct research in a manner that protects human participants, and it is the mission of the IRB to help researchers accomplish this task. - Concise review for clinicians
Migraine Headache: Updates and Future Developments
Mayo Clinic ProceedingsVol. 93Issue 11p1648–1653Published in issue: November, 2018- Parker E. Bohm
- Fernando F. Stancampiano
- Todd D. Rozen
Cited in Scopus: 13Migraine is a common disabling condition that is frequently managed by primary care providers. In recent years, the growing array of migraine therapies has added complexity to patient care. This article serves as a succinct review of pertinent updates and future directions regarding migraine. Our understanding of pathophysiology has progressed along with new advances in biomarkers and genetics. These discoveries have led to a wealth of new options for treatment, many of which are specifically targeted against molecules implicated in migraine headache such as calcitonin gene–related peptide. - Concise review for clinicians
Proton Pump Inhibitors: Review of Emerging Concerns
Mayo Clinic ProceedingsVol. 93Issue 2p240–246Published in issue: February, 2018- Avinash K. Nehra
- Jeffrey A. Alexander
- Conor G. Loftus
- Vandana Nehra
Cited in Scopus: 134First introduced in 1989, proton pump inhibitors (PPIs) are among the most widely utilized medications worldwide, both in the ambulatory and inpatient clinical settings. The PPIs are currently approved by the US Food and Drug Administration for the management of a variety of gastrointestinal disorders including symptomatic peptic ulcer disease, gastroesophageal reflux disease, and nonulcer dyspepsia as well as for prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. - Concise review for clinicians
Genitourinary Syndrome of Menopause: Management Strategies for the Clinician
Mayo Clinic ProceedingsVol. 92Issue 12p1842–1849Published in issue: December, 2017- Stephanie S. Faubion
- Richa Sood
- Ekta Kapoor
Cited in Scopus: 67Genitourinary syndrome of menopause (GSM), previously known as atrophic vaginitis or vulvovaginal atrophy, affects more than half of postmenopausal women. Caused by low estrogen levels after menopause, it results in bothersome symptoms, including vaginal dryness, itching, dyspareunia, urinary urgency and increased frequency, and urinary tract infections. Even though women with GSM can have sexual dysfunction that interferes with partner relationships, women are often embarrassed to seek treatment, and health care professionals do not always actively screen for GSM. - Concise review for clinicians
Benzodiazepine Use in Older Adults: Dangers, Management, and Alternative Therapies
Mayo Clinic ProceedingsVol. 91Issue 11p1632–1639Published in issue: November, 2016- Matej Markota
- Teresa A. Rummans
- John Michael Bostwick
- Maria I. Lapid
Cited in Scopus: 125Several major medical and psychiatric organizations, including the American Geriatrics Society, advise against using benzodiazepines or nonbenzodiazepine hypnotics in older adults. Despite these recommendations, benzodiazepines continue to be massively prescribed to a group with the highest risk of serious adverse effects from these medications. This article summarizes legitimate reasons for prescribing benzodiazepines in the elderly, serious associated risks of prescribing them, particularly when not indicated, barriers physicians encounter in changing their prescription patterns, and evidence-based strategies on how to discontinue benzodiazepines in older patients. - Concise review for cliniciansOpen Access
Counseling Patients on the Use of Electronic Cigarettes
Mayo Clinic ProceedingsVol. 90Issue 1p128–134Published in issue: January, 2015- Jon O. Ebbert
- Amenah A. Agunwamba
- Lila J. Rutten
Cited in Scopus: 29Electronic cigarettes (e-cigarettes) have substantially increased in popularity. Clear evidence about the safety of e-cigarettes is lacking, and laboratory experiments and case reports suggest these products may be associated with potential adverse health consequences. The effectiveness of e-cigarettes for smoking cessation is modest and appears to be comparable to the nicotine patch combined with minimal behavioral support. Although a role for e-cigarettes in the treatment of tobacco dependence may emerge in the future, the potential risk of e-cigarettes outweighs their known benefit as a recommended tobacco treatment strategy by clinicians. - Concise review for clinicians
Current Issues in Contraception
Mayo Clinic ProceedingsVol. 88Issue 3p295–299Published in issue: March, 2013- Mary L. Marnach
- Margaret E. Long
- Petra M. Casey
Cited in Scopus: 15Contraceptive management in women should take into account patient lifestyle and coexisting medical issues as well as method safety, efficacy, and noncontraceptive benefits. This review focuses on common and timely issues related to contraception encountered in clinical practice, including migraine headaches and associated risk of ischemic stroke, the use of combined hormonal contraception along with citalopram and escitalopram, contraceptive efficacy and safety in the setting of obesity, contraceptives for treatment of menorrhagia, the association of intrauterine contraception and decreased risk of cervical cancer, and the association of venous thromboembolism and combined hormonal contraception. - CONCISE REVIEW FOR CLINICIANS
Practical Suicide-Risk Management for the Busy Primary Care Physician
Mayo Clinic ProceedingsVol. 86Issue 8p792–800Published in issue: August, 2011- Anna K. McDowell
- Timothy W. Lineberry
- J. Michael Bostwick
Cited in Scopus: 87- Video
- Audio
Suicide is a public health problem and a leading cause of death. The number of people thinking seriously about suicide, making plans, and attempting suicide is surprisingly high. In total, primary care clinicians write more prescriptions for antidepressants than mental health clinicians and see patients more often in the month before their death by suicide. Treatment of depression by primary care physicians is improving, but opportunities remain in addressing suicide-related treatment variables. - Concise Review for Clinicians—CME Credit Offered
Bioidentical Hormone Therapy
Mayo Clinic ProceedingsVol. 86Issue 7p673–680Published in issue: July, 2011- Julia A. Files
- Marcia G. Ko
- Sandhya Pruthi
Cited in Scopus: 51The change in hormonal milieu associated with perimenopause and menopause can lead to a variety of symptoms that can affect a woman's quality of life. Postmenopausal hormone therapy (HT) is an effective, well-tolerated treatment for these symptoms. However, combined HT consisting of conjugated equine estrogen and medroxyprogesterone acetate has been associated with an increased number of health risks when compared with conjugated equine estrogen alone or placebo. As a result, some women are turning to alternative hormonal formulations known as compounded bioidentical HT because they perceive them to be a safer alternative. - CONCISE REVIEW FOR CLINICIANS
Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management
Mayo Clinic ProceedingsVol. 84Issue 7p632–638Published in issue: July, 2009- Kurt A. Kennel
- Matthew T. Drake
Cited in Scopus: 347Bisphosphonates are widely prescribed and highly effective at limiting the bone loss that occurs in many disorders characterized by increased osteoclast-mediated bone resorption, including senile osteoporosis in both men and women, glucocorticoid-associated osteoporosis, and malignancies metastatic to bone. Although they are generally well tolerated, potential adverse effects may limit bisphosphonate use in some patients. Optimal use of bisphosphonates for osteoporosis requires adequate calcium and vitamin D intake before and during therapy. - CONCISE REVIEW FOR CLINICIANS
An Update on Childhood and Adolescent Vaccines
Mayo Clinic ProceedingsVol. 84Issue 5p457–460Published in issue: May, 2009- Robert M. Jacobson
Cited in Scopus: 3In 2008, the recommendations for vaccines in children and adolescents changed substantially. The Advisory Committee on Immunization Practices expanded the routine use of influenza vaccines. New recommendations also addressed the newly licensed rotavirus vaccine. Furthermore, the Advisory Committee on Immunization Practices addressed the use of the meningococcal conjugate vaccine in children aged 2 to 10 years who are at high risk of that disease. Finally, the Food and Drug Administration and the Centers for Disease Control and Prevention reviewed the safety data collected about the human papillomavirus vaccine since its licensure and reaffirmed their recommendations for its use. - CONCISE REVIEW FOR CLINICIANS
Understanding Women's Sexual Health: A Case-Based Approach
Mayo Clinic ProceedingsVol. 83Issue 12p1382–1387Published in issue: December, 2008- Mary L. Marnach
- Petra M. Casey
Cited in Scopus: 5Female sexual dysfunction is complex and its management challenging. In this review, we discuss female sexual response and the definitions of female sexual disorders. Evidence-based strategies for the evaluation and multidisciplinary treatment of female sexual dysfunction are presented in a case-oriented manner applicable to everyday clinical practice. - CONCISE REVIEW FOR CLINICIANS
Treatment of Tobacco Dependence
Mayo Clinic ProceedingsVol. 83Issue 4p479–484Published in issue: April, 2008- Michael V. Burke
- Jon O. Ebbert
- J. Taylor Hays
Cited in Scopus: 31Cigarette smoking continues to cause substantial death and disability, but more than 1 in 5 adults smoke despite the desire among most smokers to stop and the availability of effective treatments. A systematic process to identify all smokers is crucial. Because tobacco dependence is characterized by relapses and remissions, clinicians should be ready to engage smokers and reengage relapsed smokers with options for new medication strategies and additional counseling resources. - CONCISE REVIEW FOR CLINICIANS
Treatment of Obesity
Mayo Clinic ProceedingsVol. 82Issue 1p93–102Published in issue: January, 2007- Warren G. Thompson
- David A. Cook
- Matthew M. Clark
- Aditya Bardia
- James A. Levine
Cited in Scopus: 58For primary care physicians, obesity is one of the most challenging problems confronted in office practice. The disorder is increasing in prevalence despite the efforts of both patients and physicians. Treatment requires a multimodality approach that addresses diet, physical activity, and behavioral issues. Medication and surgical approaches may be appropriate as well. This review outlines the evidence for each approach, suggests how primary care physicians can best help obese patients, and provides practical tips for weight loss. - CONCISE REVIEW FOR CLINICIANS
Hormonal Contraception Update
Mayo Clinic ProceedingsVol. 81Issue 7p949–955Published in issue: July, 2006- Paru S. David
- Elizabeth A. Boatwright
- Beverly S. Tozer
- Deepa P. Verma
- Janis E. Blair
- Anita P. Mayer
- and others
Cited in Scopus: 25Unintended pregnancy continues to be a serious public health issue in the United States. Of the 3 million unplanned pregnancies per year, 60% occur in women using some form of contraception. Educating and helping women choose a contraceptive agent that best suits their needs will improve compliance and contraceptive efficacy. A multitude of new contraceptive agents are now available. We review new hormonal contraceptive options and discuss newer oral agents, extended-cycle contraception, and innovative delivery methods. - CONCISE REVIEW FOR CLINICIANS
Diagnosis, Screening, Prevention, and Treatment of Osteoporosis
Mayo Clinic ProceedingsVol. 81Issue 5p662–672Published in issue: May, 2006- Karen F. Mauck
- Bart L. Clarke
Cited in Scopus: 120Osteoporosis is the most common bone disease in humans and affects both men and women. The clinical and public health implications of the disease are substantial because of the mortality, morbidity, and cost of medical care associated with osteoporotic fractures. Osteoporosis is diagnosed on the basis of a low-impact or fragility fracture or low bone mineral density, which was best assessed by central dual-energy x-ray absorptiometry. Both nonpharmacological therapy (calcium and vitamin D supplementation, weight-bearing exercise, and fall prevention) and pharmacological treatments (antiresorptive and anabolic agents) may be helpful in the prevention and treatment of osteoporosis. - Concise Review for Clinicians
Use of Plasma Brain Natriuretic Peptide Concentration to Aid in the Diagnosis of Heart Failure
Mayo Clinic ProceedingsVol. 78Issue 4p481–486Published in issue: April, 2003- Brian P. Shapiro
- Horng H. Chen
- John C. Burnett Jr
- Margaret M. Redfield
Cited in Scopus: 57Plasma concentration of brain natriuretic peptide (BNP), as measured by the Triage BNP Test, is approved by the Food and Drug Administration to aid in the diagnosis of heart failure. This diagnostic test is available in many institutions. The purpose of this article is to help the physician know the appropriate time to order this test and to aid in interpreting results. To achieve this goal, we review the physiology of BNP, clinical studies that support its use for diagnosing heart failure, and confounding variables to consider when BNP is being used clinically. - CONCISE REVIEW FOR CLINICIANS
Preconception Care by the Nonobstetrical Provider
Mayo Clinic ProceedingsVol. 77Issue 5p469–473Published in issue: May, 2002- Keith A. Frey
Cited in Scopus: 21Clinicians who provide health care to women during their childbearing years have the opportunity to affect pregnancy outcomes positively through preconception care. The goal of preconception care is to identify medical and social conditions that may put the mother or fetus at risk. Key elements include screening for certain infectious diseases, obtaining genetic history, updating immunizations, providing specific nutritional advice, and optimizing health status. Some women, and their partners, may require additional care, including a prepregnancy consultation with an obstetrician or maternal-fetal medicine specialist. - Concise Review for Clinicians
Medical Advice for International Travelers
Mayo Clinic ProceedingsVol. 76Issue 8p831–840Published in issue: August, 2001- Abinash Virk
Cited in Scopus: 20Each year, approximately 30 to 40 million Americans travel outside the United States. Although the most popular destinations are Europe, Central America, and the Caribbean, travel to Africa and Asia is increasing substantially. International travel, particularly to developing countries, can be associated with the risk of infectious and noninfectious diseases. These risks can be decreased, eliminated, or modified with vaccinations, prophylactic medications, and education. Optimally, pretravel advice must be individualized to a person's medical history, itinerary, and risk behavior. - Concise Review for Clinicians
Medical management of osteoarthritis
Mayo Clinic ProceedingsVol. 76Issue 5p533–539Published in issue: May, 2001- Nisha J. Manek
Cited in Scopus: 25Osteoarthritis (OA) is the most common articular disease, and it continues to be a major public health problem related to pain, disability, loss of time from work, and economics. Most patients with OA seek medical attention because of pain. In the past few years, changes in the treatment of OA have been substantial. More effective nonnarcotic analgesics, cyclooxygenase-2-specific inhibitors, nutraceuticals, and intra-articular hyaluronates are some of the new medications and agents that are now available. - Concise Review for Clinicians
Herbal Therapy: What a Clinician Needs to Know to Counsel Patients Effectively
Mayo Clinic ProceedingsVol. 75Issue 8p835–841Published in issue: August, 2000- Brent A. Bauer
Cited in Scopus: 73The use of herbal medicine in the United States has been increasing at a steady pace over the past decade. Most recent estimates suggest that the US population spends $5 billion per year for herbal supplements alone. Herbal supplements are receiving increasing exposure through national media, in lay journals, and more recently in the scientific press. Interest in herbal medicine has been facilitated by multiple factors, including the perception that. pharmaceutical medications are expensive, overprescribed, and often dangerous. - Concise Review for Clinicians
Selective Estrogen Receptor Modulators and Phytoestrogens: New Therapies for the Postmenopausal Woman
Mayo Clinic ProceedingsVol. 74Issue 6p601–607Published in issue: June, 1999- Lorraine A. Fitzpatrick
Cited in Scopus: 63Estrogen deficiency in the postmenopausal woman results in numerous symptomatic and asymptomatic manifestations, including vasomotor symptoms, osteoporosis, heart disease, bladder and vaginal symptoms, and cardiovascular disease. Estrogen replacement therapy is associated with amelioration of these problems but has attendant risks. A newer class of drugs, the selective estrogen receptor modulators, provides both estrogen agonist and antagonist properties, depending on the target tissue. This article discusses the mechanism by which selective estrogen receptor modulators may vary in their end-organ effects and reviews the clinical studies associated with these compounds. - Concise Review for Primary-Care Physicians
Recent Advances in the Management of Human Immunodeficiency Virus Infection
Mayo Clinic ProceedingsVol. 72Issue 9p854–859Published in issue: September, 1997- Zelalem Temesgen
- Alan J. Wright
Cited in Scopus: 8Major advances during the past 2 years have resulted in an unprecedented optimism regarding the perception of human immunodeficiency virus (HIV) infection. An improved understanding of the pathogenesis of HIV infection coupled with the availability of assays to measure HIV-1 RNA and the approval of new antiretroviral drugs has led to the development of new approaches to the management of HIV infection. In this article, we discuss these advances and their implications in the care of HIV-infected patients.